Hexagon Bio is a technology company.
Hexagon Bio has raised $185.0M across 3 funding rounds.
Key people at Hexagon Bio.
Hexagon Bio has raised $185.0M in total across 3 funding rounds.
Key people at Hexagon Bio.
Hexagon Bio has raised $185.0M in total across 3 funding rounds.
Hexagon Bio's investors include 8VC, Colle Capital, ff Venture Capital, N49P Ventures, Nextech Invest, Shasta Ventures, Techstars, The Column Group, Two Sigma Ventures, Vida Ventures, Bradford Cross.
Hexagon Bio is a data-driven biopharmaceutical company developing targeted small molecule therapeutics, primarily for oncology through next-generation antibody drug conjugates (ADCs).[1][2][5] Its proprietary platform integrates data science, genomics, synthetic biology, chemistry, and automation to mine fungal and microbial genomes for evolutionarily refined molecules and their protein targets, addressing unmet needs in diseases like cancer and infectious diseases.[1][2][3] The company serves patients with intractable cancers by discovering novel payloads that improve therapeutic responses and overcome resistance, with a proprietary genome database 10x larger than public ones, over 100,000 strains banked, and 80,000+ genomes sequenced.[2][3] Growth momentum includes a $77.3 million Series B financing to expand its platform, leadership promotions like Tara Arvedson to CSO, and new hires such as Victor Cee as SVP Drug Discovery.[3]
Hexagon Bio was co-founded by Maureen Hillenmeyer, Ph.D., who serves as CEO, leveraging advances in DNA sequencing, machine learning, and synthetic biology to unlock microbial metabolites for drug discovery.[3] The idea emerged from recognizing that only 1% of the world’s microbial genomes—especially fungi and bacteria—have been sequenced, yet these sources inspired breakthroughs like penicillin, statins, and oncology drugs, limited by traditional brute-force methods.[2][3] Pivotal early traction came from building a massive proprietary database through computational prediction (TICker algorithm), robotic sequencing, and compound production via the HEx platform, enabling systematic discovery of small molecules linked to disease targets.[2][3] Headquartered in Menlo Park, California, with 57 employees, the company has rapidly scaled its interdisciplinary approach across computation, biology, and chemistry.[1][3]
Hexagon Bio rides the convergence of AI-driven genomics, synthetic biology, and precision oncology, capitalizing on technologies that have sequenced just 1% of microbial genomes to reveal "hidden" natural products for modern therapies like ADCs.[2][3] Timing is ideal amid the ADC boom—current payloads derive from nature (e.g., marine mollusks, shrubs)—yet face resistance; Hexagon's platform unlocks diverse, potent alternatives for intractable cancers, influencing a market projected to grow as antibody tech matures.[2][5] Favorable forces include falling sequencing costs, ML for prediction, and investor enthusiasm for bio-AI hybrids, as seen in its Series B from life science VCs.[3] It shapes the ecosystem by expanding the "microbial natural product" paradigm, inspiring similar platforms and partnering potential with big pharma like Amgen alumni ties.[3][4]
Hexagon Bio is poised to lead metagenome-derived therapeutics, with its database and production scaling enabling a pipeline of ADC payloads and small molecules entering preclinical evaluation.[2][3] Next steps include characterizing promising compounds, optimizing for clinical candidates in oncology/infectious diseases, and potential partnerships leveraging its 10x genome edge.[3] Trends like AI-bio integration and ADC expansion (e.g., novel mechanisms beyond tubulin/DNA damage) will propel it, potentially evolving into a multi-therapeutic player rivaling traditional discovery.[2][3] As microbial mining proves its blockbuster potential—from inspiration for statins to next-gen cancer agents—Hexagon positions data-driven biopharma to redefine targeted therapies from nature's untapped vault.[2][3]
Hexagon Bio has raised $185.0M across 3 funding rounds. Most recently, it raised $77.0M Series B in October 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2022 | $77.0M Series B | 8VC, Colle Capital, ff Venture Capital, N49P Ventures, Nextech Invest, Shasta Ventures, Techstars, The Column Group, Two Sigma Ventures, Vida Ventures, Bradford Cross | |
| Sep 1, 2021 | $61.0M Venture Round | 8VC, Colle Capital, ff Venture Capital, N49P Ventures, Nextech Invest, Shasta Ventures, Techstars, The Column Group, Two Sigma Ventures, Vida Ventures, Bradford Cross | |
| Sep 1, 2020 | $47.0M Series A | 8VC, Colle Capital, ff Venture Capital, N49P Ventures, Nextech Invest, Shasta Ventures, Techstars, The Column Group, Two Sigma Ventures, Bradford Cross |
